EichorEICHOR
Location: Port Orange Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Port Orange

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · AbbVie · NCT04928846Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Canadian Cancer Trials Group · NCT06592924Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Merck Sharp & Dohme LLC · NCT03486873De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · NRG Oncology · NCT04852887A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in
Phase 3 · Nordic Lymphoma Group · NCT04332822mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Alliance for Clinical Trials in Oncology · NCT05677490Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Phase 2 · Omico · NCT06003621A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i
Phase 3 · Incyte Corporation · NCT07284849MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase N/A · Stryker Instruments · NCT03072927Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small
Phase 2/Phase 3 · National Cancer Institute (NCI) · NCT04402788Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal
Phase 3 · NRG Oncology · NCT05879926A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiv
Phase 1/Phase 2 · AbbVie · NCT06892522
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.